In addition to anti‐VEGF treatment, other anti‐angiogenic targets should also be studied, such as anti‐ANGPT, anti‐APLN, andti‐NOTCH4 and anti‐MMP2; and 3) inspired by the research of Chen et al.[39] indicating the crucial function of CAFs, we identified two types of CAFs: iCAFs mediating inflammation‐to‐cancer transformation through the interaction of cytokines and chemokines, and myCAFs engaged in ECM remodeling. This evidence concerns the gene APLN and cancer.